Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.34 |
| ▸ | STARD10 | Q9Y365 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566982 | 1.00 | ACLY (0.38) | ACLYSLC6A9CYP2C9CYP2C19AVPR2 | |
| SCHEMBL26810187 | 0.92 | SLC6A9 (0.38) | SLC6A9AVPR2GPR27EGFRFGFR1 | |
| SCHEMBL26810192 | 0.90 | GPR119 (0.40) | SLC6A9AVPR2GPR27EGFRFGFR1 | |
| SCHEMBL26810190 | 0.89 | SLC6A9 (0.40) | SLC6A9AVPR2GPR27EGFRFGFR1 | |
| SCHEMBL29566957 | 0.89 | SLC6A9 (0.39) | SLC6A9AVPR2GPR27PCTPSTARD10 | |
| SCHEMBL24310786 | 0.89 | SLC6A9 (0.39) | SLC6A9AVPR2GPR27PCTPSTARD10 | |
| SCHEMBL29566838 | 0.88 | GFER (0.39) | TSHRSMN1; SMN2EGFRFGFR1KDR | |
| SCHEMBL24310039 | 0.88 | GFER (0.39) | TSHRSMN1; SMN2EGFRFGFR1KDR | |
| SCHEMBL26810218 | 0.86 | KMT2A (0.40) | TSHRSMN1; SMN2EGFRFGFR1KDR | |
| SCHEMBL24310791 | 0.86 | EGFR (0.38) | ACLYTSHRSMN1; SMN2EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ACLY 1453/4885SLC6A9 822/4885CYP2C9 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.